這是一項先導研究，旨在識別伴有淋巴結或遠端轉移的胃癌患者中的新型治療分子靶點。所有在威爾斯親王醫院確診為伴有轉移的胃癌患者均將接受資格篩查。
適應症：Stomach Neoplasms, Benign
收案條件
納入條件
- Patients age \>= 18, \<= 80 years old
- Performance status (WHO) \<=2
- Gastric adenocarcinoma with lymph node metastasis or distant metastasis such as liver metastases, lung metastases, bone metastases, peritoneum metastases
- Patients with isolated ovarian metastasis could be included
- Patients who will be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy
- Ability to give written consent before the commencement of treatment
排除條件
- Patient who will not be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy
- Pregnancy or breastfeeding
- Patients with irreversible coagulation disorders
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。